



# Mitochondrial sulfide promotes life span and health span through distinct mechanisms in developing versus adult treated *Caenorhabditis elegans*

Adriana Raluca Vintila<sup>a,1</sup> , Luke Slade<sup>a,b,1</sup> , Michael Cooke<sup>a,c,1</sup> , Craig R. G. Willis<sup>d</sup>, Roberta Torregrossa<sup>b</sup> , Mizanur Rahman<sup>e</sup>, Taslim Anupom<sup>f</sup>, Siva A. Vanapalli<sup>e</sup> , Christopher J. Gaffney<sup>g</sup> , Nima Gharahdaghi<sup>b</sup>, Csaba Szabo<sup>h</sup> , Nathaniel J. Szewczyk<sup>c,i</sup> , Matthew Whiteman<sup>b,2</sup> , and Timothy Etheridge<sup>a,2</sup>

Edited by Ronald DePinho, The University of Texas MD Anderson Cancer Center, Houston, TX; received September 21, 2022; accepted May 30, 2023

Living longer without simultaneously extending years spent in good health (“health span”) is an increasing societal burden, demanding new therapeutic strategies. Hydrogen sulfide (H<sub>2</sub>S) can correct disease-related mitochondrial metabolic deficiencies, and supraphysiological H<sub>2</sub>S concentrations can pro health span. However, the efficacy and mechanisms of mitochondrion-targeted sulfide delivery molecules (mtH<sub>2</sub>S) administered across the adult life course are unknown. Using a *Caenorhabditis elegans* aging model, we compared untargeted H<sub>2</sub>S (NaGGY4137, 100 μM and 100 nM) and mtH<sub>2</sub>S (AP39, 100 nM) donor effects on life span, neuromuscular health span, and mitochondrial integrity. H<sub>2</sub>S donors were administered from birth or in young/middle-aged animals (day 0, 2, or 4 postadulthood). RNAi pharmacogenetic interventions and transcriptomics/network analysis explored molecular events governing mtH<sub>2</sub>S donor-mediated health span. Developmentally administered mtH<sub>2</sub>S (100 nM) improved life/health span vs. equivalent untargeted H<sub>2</sub>S doses. mtH<sub>2</sub>S preserved aging mitochondrial structure, content (citrate synthase activity) and neuromuscular strength. Knockdown of H<sub>2</sub>S metabolism enzymes and FoxO/*daf-16* prevented the positive health span effects of mtH<sub>2</sub>S, whereas DCAF11/*wdr-23* – Nrf2/*skn-1* oxidative stress protection pathways were dispensable. Health span, but not life span, increased with all adult-onset mtH<sub>2</sub>S treatments. Adult mtH<sub>2</sub>S treatment also rejuvenated aging transcriptomes by minimizing expression declines of mitochondria and cytoskeletal components, and peroxisome metabolism hub components, under mechanistic control by the *elt-6/elt-3* transcription factor circuit. H<sub>2</sub>S health span extension likely acts at the mitochondrial level, the mechanisms of which dissociate from life span across adult vs. developmental treatment timings. The small mtH<sub>2</sub>S doses required for health span extension, combined with efficacy in adult animals, suggest mtH<sub>2</sub>S is a potential healthy aging therapeutic.

health span | longevity | mitochondria | transcriptomics | H<sub>2</sub>S

Medical advances mean humans are living longer but are also spending longer in a frail “poor health” state (1, 2), with large burdens on healthcare systems and quality of life (3). Since most age-related healthcare costs and patient frailty occur in the later years of life (1, 2), interventions that increase life span without simultaneously increasing health span would be detrimental to the aging process. Studies often report life span–extending therapeutics in lower organisms (4, 5), but a significant caveat is the general assumption that increasing longevity also prolongs the duration spent in a healthy state (termed “health span”). While it is largely unknown whether most conditions that extend life span also increase health span, evidence indicates dissociation between the two (6). For example, all long-lived *Caenorhabditis elegans* mutants examined to date spend a longer time in an aged frail condition (7); the same phenomenon reported in long-living humans (1, 2). Therapeutic approaches that extend healthy years, rather than life span alone, thus hold considerable socioeconomic potential.

Hydrogen sulfide (H<sub>2</sub>S) was one of the essential ingredients required for life to emerge on Earth (8, 9) and has emerged as an important, physiologically relevant signaling molecule. When applied exogenously, H<sub>2</sub>S treatments, usually in the form of crude impure sulfide salts at supraphysiological concentrations (e.g. >100 μM), confer cytoprotective properties across various pathophysiological states (9–14), including age-associated diseases (15, 16). Accordingly, 100 to 150 μM concentrations of untargeted H<sub>2</sub>S donors such as GYY4137 and FW1256 extend both life span (17–19) and health span (20) in *C. elegans* when administered from birth. However, several essential biochemical processes are established during development that program subsequent adult behavior. For example, developmental starvation cements locomotion circuitry that impacts adult foraging behavior

## Significance

Deteriorating health across the life course is a major societal burden, and effective therapeutics are lacking. Mitochondrial decline has long been associated with age-related health loss. We show that small, clinically meaningful doses of a mitochondrion-targeting sulfur donor (AP39) extend *Caenorhabditis elegans* health in older age, which act by maintaining mitochondrial integrity. Adult onset of AP39 delivery, when mitochondrial and cell structural dysfunction are already manifested, also promoted healthy aging. Distinct association of health span extension with mitochondria, cytoskeletal and peroxisome molecular profiles, under regulation of the *elt-6/elt-3* transcription factor regulatory circuit, further distinguished adult-onset AP39 therapy. Our results establish a framework for forward translating mitochondrial sulfide as a potentially viable healthy aging intervention in mammals.

This article is a PNAS Direct Submission.

Copyright © 2023 the Author(s). Published by PNAS. This open access article is distributed under [Creative Commons Attribution License 4.0 \(CC BY\)](https://creativecommons.org/licenses/by/4.0/).

<sup>1</sup>A.R.V., L.S., and M.C. contributed equally to this work.

<sup>2</sup>To whom correspondence may be addressed. Email: m.whiteman@exeter.ac.uk or t.etheridge@exeter.ac.uk.

This article contains supporting information online at <https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2216141120/-DCSupplemental>.

Published July 31, 2023.

(21), and developmentally established mitochondrial dynamics determine rates of adult respiration and aging (22). Additionally, life-extending mitochondrial interventions in *C. elegans* currently require administration on or before the developmental larval stages (23). Metabolic patterns set during developmental H<sub>2</sub>S treatments might, therefore, mediate life span and health span extension. The efficacy of H<sub>2</sub>S administered during “normal” stochastic aging thus warrants investigation to understand the viability of adult H<sub>2</sub>S-based therapies.

Several cellular processes are responsive to H<sub>2</sub>S that can regulate H<sub>2</sub>S-mediated longevity (18), yet the mechanisms governing H<sub>2</sub>S-mediated health span are undefined. Increasing evidence supports a mitochondrion-centric mode of H<sub>2</sub>S action across cell types and pathologies. Current dogma suggests H<sub>2</sub>S donates electrons to the mitochondrial electron transport chain, inhibits mitochondrial cAMP phosphodiesterases, facilitates mitochondrial DNA repair, promotes mitochondrial antioxidant protection, and augments mitochondrial respiration/ATP production (reviewed in ref. 24). Moreover, mitochondrial loss is one of the nine hallmarks of aging (25) and is the earliest detectable subcellular structural change during *C. elegans* aging (26), preceding physiological decline (27). As such, therapies that exploit positive H<sub>2</sub>S effects on mitochondria represent an attractive antiaging strategy. The mitochondrial sulfide delivery molecule (mtH<sub>2</sub>S), AP39, exploits mitochondrial membrane potential by utilizing a TPP<sup>+</sup> motif to localize H<sub>2</sub>S to the mitochondria and protect against cellular injury [e.g., glucose oxidase-induced mitochondrial dysfunction (28)] vs. equal doses of untargeted H<sub>2</sub>S donors. Consequently, unlike untargeted H<sub>2</sub>S compounds (e.g., GYY4137, FW1256) with supraphysiological effective doses (17–20), mtH<sub>2</sub>S displays potency at concentrations several orders of magnitude lower in *C. elegans* disease models (13, 14). Whether such phenomena occur in the aging context is unknown; however, mtH<sub>2</sub>S is plausibly responsible for longevity and health span extension reported following larger untargeted H<sub>2</sub>S doses.


This study, therefore, investigated the efficacy of a mtH<sub>2</sub>S (AP39) for promoting health span via mitochondrion-mediated effects vs. untargeted H<sub>2</sub>S donors, using *C. elegans* as an aging model. Given the unknown capacity of H<sub>2</sub>S as an efficacious therapy in aging adults, we also examined health span effects of adult-onset H<sub>2</sub>S treatments. Using functional pharmacogenetic approaches, we provide evidence that mtH<sub>2</sub>S is a requirement for, and site of action of, H<sub>2</sub>S-mediated health span promotion. Importantly, mtH<sub>2</sub>S increases health span when administered to young and middle-aged adults, and this adult treatment effect is clearly reflected at the

transcriptomic level compared to developmental mtH<sub>2</sub>S administration, under the control of a GATA family of transcription factors. These findings strongly suggest that augmentation of mitochondrial sulfide may represent a druggable target and translatable therapeutic approach to maintaining health with advancing age, at time points where the negative effects of aging already manifest.


## Results

**mtH<sub>2</sub>S Increases *C. elegans* Life span and Neuromuscular Health span.** We first investigated the effects of mitochondrion-targeted and nontargeted H<sub>2</sub>S donors on *C. elegans* life span. Dosing L1 larvae with the untargeted sulfide donor NaGYY4137 (100 μM) increased maximal life span by 20% ( $P < 0.0001$ ) (Fig. 1A), which is comparable to previous studies using GYY4137 (morpholine salt) and related compounds (18, 19). In sharp contrast, the mitochondrion-targeted sulfide delivery molecule (mtH<sub>2</sub>S) AP39 significantly increased life span at 1000-fold lower doses (100 nM) by 30% ( $P < 0.0001$ ) (Fig. 1B), whereas equivalent 100 nM doses of untargeted NaGYY4137 had no significant effect on *C. elegans* life span extension (Fig. 1A).

We next assessed movement rates on days 0, 2, 4, 8, 12, and 16 of life span as a robust proxy of overall animal health (29–31) and, therefore, health span. Using wMicroTracker to measure prolonged movement capacity beyond standard thrash assays (32), wild-type movement capacity peaked at day 4 of adulthood (+97% vs. day 0 baseline), as previously published (33, 34), and progressively declined thereafter to a nadir of –26% at day 16 (SI Appendix, Fig. S1). At greatly different doses, 100 μM NaGYY4137 H<sub>2</sub>S and 100 nM mtH<sub>2</sub>S increased total animal movement rates across the life course ( $P < 0.001$ ), using area under the curve analysis of movement across the life course, as previously published (30) (Fig. 2A). Post hoc analysis showed significant health span extension in mtH<sub>2</sub>S (100 nM)-treated animals up to day 16 postadulthood compared to day 12 postadulthood during NaGYY4137 treatments (SI Appendix, Fig. S1). Loss of neuromuscular strength is also one of the strongest correlates of all-cause mortality in humans (29, 35), leading us to employ our “NemaFlex” device (36–38) to examine neuromuscular strength changes across age. As with movement rates (SI Appendix, Fig. S1), wild-type strength capacity increased between days 0 and 4 adulthood and declined thereafter. Conversely, treatment with mtH<sub>2</sub>S (100 nM) improved strength production across days 0–10 postadulthood ( $P < 0.001$ ), with a significant 20% strength increase vs. wild-type at day 10 (Fig. 2B). Additionally, while the observed effect sizes of mtH<sub>2</sub>S



**Fig. 1.** Lower doses of mitochondrion-targeted H<sub>2</sub>S extend life span. (A) *C. elegans* life span is significantly increased with higher (100 μM), but not lower (100 nM) treatment with the untargeted H<sub>2</sub>S donor, NaGYY4137 when administered from L1 larval stage across the entire lifecycle. (B) Conversely, lower doses (100 nM) of mitochondrion-targeted H<sub>2</sub>S (AP39) extend life span. Life span curves represent the average of three biological replicates (total ~300 to 600 animals per condition). \*\*\*\* denotes significant difference vs. untreated (0.01% DMSO) wild-type controls ( $P < 0.0001$ ). ns, nonsignificant.



**Fig. 2.** Mitochondrion-targeted H<sub>2</sub>S extends movement rate and maximal strength indices of health span. (A) Animal movement rate is increased across the entire lifespan with both lower dose (100 nM) mitochondrion-targeted H<sub>2</sub>S (AP39) and higher dose (100 µM) untargeted H<sub>2</sub>S (NaGY4137) when administered from L1 larval stage until death. Movement rates as a % change from day 0 baselines, across days 0, 2, 4, 8, 12, and 16 postadulthood, are presented as area under the curve. (B) Lower dose (100 nM) mitochondrion-targeted H<sub>2</sub>S maintains *C. elegans* maximal strength producing ability in later life (day 10 postadulthood), measured using our microfluidic NemaFlex device. Data presented are mean ± SD, n = 90 per condition, across 3 biological replicates. \*P < 0.05, \*\*P < 0.01 and \*\*\*\*P < 0.0001 denotes significant difference vs. untreated (0.01% DMSO) wild-type controls.

are comparable to those reported for other life span-extending compounds (39–41), the improvements we observed are modest. We, therefore, directly compared mtH<sub>2</sub>S to a recently published life span and health span improving drug, rilmenidine (42), using our microfluidic “Nemalife” health span device, and found both compounds extended life span and health span to similar degrees using our microfluidic approach (SI Appendix, Fig. S2). Rilmenidine also has no effect on neuromuscular health parameters in early life (42) but rather manifest in older age time points, as observed herein for mtH<sub>2</sub>S. Collectively, these data strongly suggest that H<sub>2</sub>S effects on health span are likely mediated through mitochondrial effects which, although modest, may be highly beneficial, since aging is also associated with a later life loss of prolonged movement and strength-producing capacity.


**mtH<sub>2</sub>S Maintains Mitochondrial Structure and Content.** Given the well-established role of mitochondrial dysfunction in age-related health decline across species (25), we examined whether mtH<sub>2</sub>S health span promotion associated with maintained mitochondrial integrity. Using green fluorescent protein-tagged mitochondrion transgenic animals to compare lower dose mtH<sub>2</sub>S (100 nM) to higher dose untargeted H<sub>2</sub>S (100 µM), mitochondrial structure was scored as either well networked, or moderately fragmented. Well-networked mitochondria at day 0 of adulthood presented in 88% of wild-type animals, which was not affected by either mtH<sub>2</sub>S or untargeted H<sub>2</sub>S treatments. In line with previous reports (26), by day 2 postadulthood well-networked mitochondria reduced

to 21% in wild-type worms. The number of well-networked mitochondria increased threefold with mtH<sub>2</sub>S treatment at day 2 of adulthood, and twofold with untargeted H<sub>2</sub>S (P < 0.001). Only mtH<sub>2</sub>S significantly sustained mitochondrial integrity at day 4 postadulthood (Fig. 3A). In wild-type animals, the number of moderately fragmented mitochondria increased progressively from day 2 of adulthood (21% of animals), reaching 86% by day 16. Comparable delays in moderate mitochondrial fragmentation were observed between mtH<sub>2</sub>S and untargeted H<sub>2</sub>S from days 8 to 12 postadulthood, whereas only mtH<sub>2</sub>S suppressed moderate fragmentation up to day 14 of adulthood (Fig. 3B). We also assessed citrate synthase activity (CS) as a marker of mitochondrial health, which correlates with mitochondrial content, biosynthesis, and cristae area (43). Untargeted H<sub>2</sub>S failed to induce a significant effect on CS across the life course. Conversely, mtH<sub>2</sub>S significantly increased CS throughout life span, and to a greater extent than untargeted H<sub>2</sub>S (up to day 12, P < 0.0001), with significant increases in CS presenting up to day 4, but not day 12 of life span (Fig. 3E). To confirm that differences in H<sub>2</sub>S bioavailability does not underpin the improved efficacy of mtH<sub>2</sub>S vs. untargeted H<sub>2</sub>S for maintaining mitochondrial structure and content, we assessed total animal sulfide levels and found no difference with either compound at day 4 postadulthood (SI Appendix, Fig. S3). Thus, mtH<sub>2</sub>S improves mitochondrial integrity across age, which associates with health span maintenance.

#### AP39-Mediated Health span Extension Requires H<sub>2</sub>S Metabolism and FoxO Pathways, but Not Nrf2 Oxidative Stress Protection.

Several mechanisms have been proposed to regulate longevity in response to exogenous H<sub>2</sub>S (19), yet the mechanisms governing health span extension are unknown. To probe this, we performed a hypothesis-driven RNAi gene knockdown and a mtH<sub>2</sub>S pharmacogenetic screen, using a microfluidic life span machine to assess animal health every day of the life course. First, we examined the requirement for enzymes controlling endogenous H<sub>2</sub>S synthesis: cytosolic cystathionine-β-synthase (CBS/*cbs-1*) and cystathionine-γ-lyase (CSE/*cth-2*), and cytoplasmic/mitochondrial 3-mercaptopyruvate sulfurtransferase (3-MST/*mpst-1*) (8–10). Corroborating previous reports, we found that *cth-2* knockdown alone had no effect on life span (19) and knocking down *cbs-1* or *mpst-1* shortened life span (19, 44) (SI Appendix, Fig. S4). Knockdown of *cth-2* also did not significantly affect health span, whereas knockdown of *cbs-1* and *mpst-1* RNAi both impaired health span (SI Appendix, Fig. S4). Cotreatment of RNAi against *cth-2*, *cbs-1* or *mpst-1* with mtH<sub>2</sub>S from L1 stage prevented the positive effects of mtH<sub>2</sub>S on life span and health span (Table 1 and SI Appendix, Fig. S4). While exogenous mtH<sub>2</sub>S might be anticipated to bypass endogenous H<sub>2</sub>S biosynthesis pathways, analysis of total animal sulfide levels confirmed a need for functional H<sub>2</sub>S producing enzymes, since mtH<sub>2</sub>S-induced sulfide increases in older age were ablated when combined with *cth-2*, *mpst-1* or *cbs-1* RNAi (SI Appendix, Fig. S5). Combined with the loss of mtH<sub>2</sub>S-induced life span and health span extension with knockdown of the H<sub>2</sub>S synthesizing enzymes *kri-1* and *cysl-2* (Table 1 and SI Appendix, Fig. S4), the H<sub>2</sub>S synthesis system is a general requirement for the positive effects of mtH<sub>2</sub>S donors on *C. elegans* health and longevity.

We next examined the potential involvement of enzymes involved in wider H<sub>2</sub>S metabolism: ETHE1/*ethe-1*, a mitochondrial sulfur dioxygenase necessary for H<sub>2</sub>S catabolism (45), and GSR/*gsr-1*, a glutathione reductase involved in H<sub>2</sub>S-mediated production of glutathione (46). Knockdown of *ethe-1* alone did not affect life span but significantly increased health span and, when combined with mtH<sub>2</sub>S, prevented mtH<sub>2</sub>S-induced life span



**Fig. 3.** mtH<sub>2</sub>S prolongs mitochondrial integrity and content. (A) The percentage of well-networked and (B) moderately fragmented mitochondria during *C. elegans* aging is significantly improved with mtH<sub>2</sub>S (AP39), and for a longer duration than untargeted H<sub>2</sub>S (NaGY4137) treatments. Data represent two biological replicates (total ~80 animals per time point/condition and 450 muscle cells). (C, D) Representative green fluorescent protein-tagged mitochondrial images for normally arrayed (Left) and moderately fragmented (Right) mitochondria. White dashed boxes and corresponding magnified panels (Right) highlight each structural phenotype. (E) Citrate synthase activity with mtH<sub>2</sub>S at young adulthood (day 0) and day 4 postadulthood with mtH<sub>2</sub>S treatment, but not with untargeted H<sub>2</sub>S. Data represent two biological replicates, each with technical triplicates (total ~50 animals per time point/condition). All data are mean ± SD. \**P* < 0.05, \*\**P* < 0.01, \*\*\**P* < 0.001, \*\*\*\**P* < 0.0001 denote significant difference from untreated (0.01% DMSO) wild-type controls.

and health span extension. Because *ethe-1* catabolizes H<sub>2</sub>S, we postulated that harmful H<sub>2</sub>S accumulation might occur following combined exogenous mtH<sub>2</sub>S administration. Examining the dose response (1 nM to 2 μM) of mtH<sub>2</sub>S + *ethe-1* knockdown revealed no further decline in animal health span, however life span became shortened at higher (100 nM to 2 μM) doses (*SI Appendix, Fig. S6*). Both life span and health span were reduced following *gxr-1* knockdown, which also inhibited life/health span extension with concurrent mtH<sub>2</sub>S treatment. Additionally, the FoxO/*daf-16* transcription factor has been implicated in H<sub>2</sub>S life span extension (19), and we observed lowered life span and health span with *daf-16* knockdown alone, corroborating previous reports (47). mtH<sub>2</sub>S did not increase life span or health span in animals subjected to *daf-16* RNAi (Table 1 and *SI Appendix, Fig. S4*).

H<sub>2</sub>S also regulated cellular redox homeostasis, in part through activation of the Nrf2 transcription factor and associated signaling pathway (48). We, therefore, knocked down Nrf2/*skn-1* or DCAF11/*wdr-23* as a negative upstream regulator of Nrf2 (49). In

line with previous reports (50) *skn-1* knockdown animals were short lived, whereas *wdr-23* deficient worms were longer lived. Both *skn-1* and *wdr-23* RNAi also resulted in extended health span. Agreeing with earlier studies showing a need for the Nrf2 system for H<sub>2</sub>S-induced *C. elegans* life span extension (44), we also observed prevention of mtH<sub>2</sub>S increases in life span with combined *skn-1* or *wdr-23* knockdown. Despite this, our findings reveal that the Nrf2 system is not required for mtH<sub>2</sub>S-associated health span extension. We observed this same phenomenon with other components of the Nrf2 pathway, including the Nrf2-controlled glutamate–cysteine ligase catalytic subunit, GCLC/*gcs-1*. Only the Nrf2 nuclear translocation regulatory factor RelA/*ikke-1* attenuated mtH<sub>2</sub>S health span improvements (Table 1 and *SI Appendix, Fig. S4*). Our data strongly suggest that the positive health span effects of mtH<sub>2</sub>S were not dependent on the Nrf2 signaling system.

Last, we investigated the role of two H<sub>2</sub>S-responsive candidates, the mitochondrion-located heat shock protein chaperone HSPA9/*hsp-6* (44), and the hypoxia inducible transcription

**Table 1. Summary of mechanisms regulating mtH<sub>2</sub>S-induced life span and health span extension**

	Gene target	Human Gene	Gene description	Required for positive effects of mtH <sub>2</sub> S?	
				Life span	Health span
H <sub>2</sub> S synthesis	<i>mpst-1</i>	MPST	Mitochondrial H <sub>2</sub> S synthesis	✓	✓
	<i>cth-2</i>	CTH	Mitochondria-translocating H <sub>2</sub> S synthesis	✓	✓
	<i>cbs-1</i>	CBSL	Cytosolic H <sub>2</sub> S synthesis	✓	✓
	<i>kri-1</i>	KRIT 1	H <sub>2</sub> S and ROS generation	✓	✓
	<i>cysl-2</i>	Cysteine synthase	Cytosolic H <sub>2</sub> S production	✓	✓
H <sub>2</sub> S oxidation/redox	<i>ethe-1</i>	ETHE1	Dioxygenase required for H <sub>2</sub> S oxidation	✓	✓
	<i>gsr-1</i>	GSR	Glutathione reductase	✓	✓
H <sub>2</sub> S + aging	<i>daf-16</i>	FoxO	H <sub>2</sub> S responsive FoxO transcription factor	✓	✓
Nrf2 oxidative stress protection	<i>skn-1</i>	NRF2	Regulates oxidate stress response	✓	×
	<i>gcs-1</i>	GCLC	Glutathione synthesis under Nrf2 control	✓	×
	<i>ikke-1</i>	RELA	Regulates Nrf2 nuclear translocation	×	✓
	<i>wdr-23</i>	Keap1	Negative regulator of Nrf2	×	×
H <sub>2</sub> S responsive	<i>hif-1</i>	HIF	H <sub>2</sub> S-responsive transcription factor	×	×
	<i>hsp-6</i>	Hsp70	H <sub>2</sub> S-responsive mitochondrial chaperone	×	×

*C. elegans* were treated with mtH<sub>2</sub>S (100 nM) from L1 larval stage in the presence or absence of RNAi against each target gene, using our microfluidic healthspan device. Each experiment was performed in duplicate (total ~160 animals per condition) and health span data expressed as area under the curve (% movement rate of each day of the lifecourse vs. day 0 baseline values). Ticks denote RNAi knockdown prevents significant ( $P < 0.05$ ) mtH<sub>2</sub>S life span or health span extension and compared to untreated (0.01% DMSO) empty vector controls. Crosses denote RNAi knockdown does not prevent significant ( $P < 0.05$ ) mtH<sub>2</sub>S-induced life span or health span extension. All raw data are provided in [SI Appendix, Fig. S4](#).


factor HIF1A/ *hif-1* (44). Knockdown of both *hsp-6* or *hif-1* significantly increased life span and health span, and combined gene knockdown with mtH<sub>2</sub>S did not impact the life span and health span promoting effects of mtH<sub>2</sub>S (Table 1 and [SI Appendix, Fig. S4](#)).

#### Adult Treatments with mtH<sub>2</sub>S Extend Health span, but Not Life span.

Life span and health span extension have only been previously reported with untargeted H<sub>2</sub>S continuously administered from L1 larval stage until death. We, therefore, treated animals with low (100 nM) dose AP39 or 1000-fold higher (100 μM) dose NaGYY4137, starting in either day 0 young adults, day 2 of adulthood (chosen as the time point of mitochondrial fragmentation onset, Fig. 4A and ref. 26), or day 4 of adulthood [chosen as the time point when tissue structural integrity begins to decline (26)]. Both mtH<sub>2</sub>S and untargeted H<sub>2</sub>S donors were ineffective at increasing animal life span when administered from day 0, 2, or 4 of adulthood ( $P > 0.05$ ). Conversely, health span was significantly increased by mtH<sub>2</sub>S when administered from either day 0, 2, or 4 of adulthood ( $P < 0.01$ ) and was also increased with untargeted H<sub>2</sub>S treatments starting from days 2 or 4 postadulthood ( $P < 0.05$ ), but not in day 0 young adults (Fig. 4 and [SI Appendix, Fig. S7](#)). Additionally, mtH<sub>2</sub>S administered from day 0 adulthood significantly increased the number of normally arrayed mitochondria at days 4 and 10 postadulthood, and improved sarcomere organization at day 10 postadulthood ([SI Appendix, Fig. S8](#)). Providing further evidence that improved mitochondrial health underpins mtH<sub>2</sub>S health improvements, we also found significantly lower mitochondrial superoxide levels during aging with adult mtH<sub>2</sub>S treatment ([SI Appendix, Fig. S9](#)). Health span was thus extended when mtH<sub>2</sub>S was delivered to adult animals, at time points where key aging subcellular defects occur, and is reflected in delayed onset of age-related dystrophic muscle and dysfunctional mitochondria.

#### Adult mtH<sub>2</sub>S Treatments Maintain Mitochondrion- and Peroxisome-Enriched Transcriptomes in Later Life.

To better understand the molecules governing life span and health span responsiveness to mtH<sub>2</sub>S, we performed next-generation sequencing on animals treated with mtH<sub>2</sub>S from L1 larvae or from day 0 of adulthood. Principal component analysis revealed distinct features of *C. elegans* transcriptomes across days 0, 4, and 10 postadulthood. Moreover, mtH<sub>2</sub>S-treated animals displayed similar gene features to wild-type at day 0 and 4 of adulthood. Divergence from wild-type presented in older day 10 animals, with a shift toward day 4 features in mtH<sub>2</sub>S treatments, particularly when treated from day 0 young adulthood (Fig. 5A). Consistent with principal component analysis, global transcriptomic dysregulation at day 10 postadulthood was reduced in animals treated with mtH<sub>2</sub>S at adult onset only (Fig. 5B). Next, clustering of differentially expressed genes using expression profiles (51–53) identified four most prominent differentially expressed gene clusters (i.e., clusters containing >200 differentially expressed genes). Two of these (Clusters 8 and 14) exhibited an elevated expression profile in later life (day 10 postadulthood) that was suppressed with adult onset mtH<sub>2</sub>S but unaffected by mtH<sub>2</sub>S administered from birth (L1 stage), and were functionally associated with FoxO, proteolytic, mitophagy, and ribosome translational processes (Fig. 5C and D). Analyzing the top 10 ranked protein–protein interaction (PPI) network hub nodes for each cluster identified *daf-2*-responsive F-box genes (*fbxb-41*, *fbxb-54*, *fbxb-91*, *M116.1*, *pes-2.2*, *T05D4.2*, *T25E12.6*) and autophagy (*C35E7.5*) components as prominent cluster 8 hubs. Cluster 14 hubs aligned almost exclusively to nucleolus localized components (*lpd-7*, *nol-6*, *nol-14*, *pro-3*, *rpl-24.2*) involved in RNA-binding activity as part of the ribonucleoprotein complex (*F49D11.10*, *rbm-28*, *toe-1*, *W09C5.1*, *Y45F10D.7*). As with wider cluster expression profiles, gene expression of hub components was predominantly altered at day 10 older age and in response to adult mtH<sub>2</sub>S treatments only (Fig. 5E).




**Fig. 4.** Adult-onset treatment with mitochondrion-targeted H<sub>2</sub>S extends health span but not life span. (A–C) Survival curves are unaffected vs. wild-type ( $P > 0.05$ ) with 100 nM mtH<sub>2</sub>S and 100  $\mu$ M untargeted H<sub>2</sub>S treatments beginning at day 0, 2 or 4 of adulthood. (D–F) mtH<sub>2</sub>S significantly increases health span when administered from day 0, 2, or 4 of adulthood, and untargeted H<sub>2</sub>S improves health span when administered from day 2 or 4 postadulthood, analyzed as area under the curve,  $n = 360$  per condition, across 3 biological replicates and 18 technical replicates. Life span data are  $\sim 300$  animals per condition, across three biological replicates. \* $P < 0.05$ , \*\*\* $P < 0.001$  and \*\*\*\* $P < 0.0001$ ) denotes significant difference vs. untreated (0.01% DMSO) wild-type controls.

Moreover, two gene clusters (Clusters 3 and 13) that aligned to cytoskeletal structure, mitochondria, and general metabolism functional classes, displayed progressive expression declines with age. In both clusters, mtH<sub>2</sub>S administered from L1 again failed to affect the age-related loss of gene expression. Conversely, adult-onset mtH<sub>2</sub>S treatment induced a strong maintenance of gene expression, emerging specifically in day 10 adults (Fig. 5 C and D). Additionally, this pattern of age-related gene expression changes remaining unaltered by L1 mtH<sub>2</sub>S administration, but rejuvenated by adult-onset mtH<sub>2</sub>S in later life emerged across nearly all other 27 gene clusters identified (SI Appendix, Table S1 and Fig. S10). Top ranked hubs for cluster 3 related mostly to muscle cytoskeletal proteins (*C46G7.2*, *cpn-3*, *mlc-1*, *mup-2*, *tnt-2*, *unc-27*), but included regulators of calcium homeostasis (*csq-1*) and glutathione transferase activity (*gst-26*). Within cluster 13, there was striking enrichment for hubs functionally associated with peroxisomal components (*acox-1.1*, *acox-1.2*, *B0272.4*, *ctl-2*,

*daf-22*, *dhs-28*) and lysosomal cathepsin proteases (*asp-1*, *asp-3*). Again, only adult-onset mtH<sub>2</sub>S treatments appeared to attenuate the age-related reduction in gene expression of hub components, in older day 10 animals (Fig. 5E). To probe the mechanistic influence of these hub genes in the positive aging effects of adult-onset mtH<sub>2</sub>S, we examined the requirement of the peroxisomal catalase *ctl-2* as the most strongly maintained hub gene across clusters 3, 8, 13, and 14 (Fig. 5E). RNAi knockdown of *ctl-2* exacerbated early adult mitochondrial fragmentation and prevented the mtH<sub>2</sub>S-induced mitochondrial maintenance in early and later life (SI Appendix, Fig. S11), therein supporting the functional and mechanistic relevance of our identified transcriptomic targets.

**A GATA Transcription Factor Regulatory Circuit Underpins the Positive Aging Effects of mtH<sub>2</sub>S.** We next sought to examine the mechanistic role of genes responsive to mtH<sub>2</sub>S during aging; however, the clusters identified represent several dozen individual differentially



**Fig. 5.** Effects of age and mtH<sub>2</sub>S on the *C. elegans* transcriptome. (A) Principal component (PC) analysis plot of all analyzed samples. (B) Differential gene quantities with time and between conditions. (C) Truncated violin plots depicting time/condition expression trends (represented as Z-score of gene abundance) for clusters of differentially expressed genes >200 genes in size. \* = cluster genes have median FDR < 0.05 for given comparison with day 0 untreated (0.01% DMSO) wild-type animals,  $\Phi$  = cluster genes have median FDR < 0.05 for direct comparison between treatments at given time point. (D) Representative term enrichments for each cluster shown in panel C. (E) Expression heatmap for top connected PPI network components for each gene cluster shown in panel C. Data represent ~60 animals across biological triplicates, per condition and time point. For all panels, WT = wild-type. D0, D4 and D10 = days 0, 2 and 4 postadulthood, respectively.

expressed genes. We, therefore, employed transcription factor (TF)-binding site analysis to identify TFs predicted to commonly regulate the cytoskeletal (Cluster 3) and peroxisomal (Cluster 13) gene

clusters that display mtH<sub>2</sub>S-induced preservation in older age. From this, a single transcription factor, *elt-3* (part of a GATA family of transcription factors), emerged as the putative regulator of both gene

clusters (Fig. 5D). During wild-type aging, expression of *elt-5* and *elt-6* increase which, in turn, repress expression of *elt-3* to regulate a large portion of age-related transcriptome changes (54). Our untreated controls mirrored this response at the transcriptional level, and these expression changes are reversed by adult onset mtH<sub>2</sub>S (SI Appendix, Fig. S12). Next, using transgenic animals coexpressing ELT-6 RFP and mitochondrial GFP reporters, we confirmed protein level ELT-6 upregulation during aging, which was suppressed by adult onset mtH<sub>2</sub>S treatment (Fig. 6A and B), and corresponded with improved mitochondrial structure and movement rates (Fig. 6C and D). Additionally, knockdown of either *elt-6* or *elt-3*, while not affecting animal movement rate in middle age and older age, prevented mtH<sub>2</sub>S-induced movement increases (Fig. 6E and F).

To verify the role of *elt-6/elt-3*, we examined the cytoskeleton (adherens junction) and mitochondrion-localized protein BAR-1/ $\beta$ -catenin, loss of which is reported to up-regulate gene clusters under regulation by *elt-3* (55) which would, therefore, be anticipated to also down-regulate ELT-6. Consistent with this model, we observed that *bar-1* RNAi prevented age-related increases in ELT-6 expression (SI Appendix, Fig. S13). Moreover, mtH<sub>2</sub>S did not synergistically lower age-related ELT-6 levels when combined with *bar-1* RNAi (SI Appendix, Fig. S13), implying some functional association with mtH<sub>2</sub>S and *bar-1*/ $\beta$ -catenin (further supporting a role for mtH<sub>2</sub>S in modifying the cytoskeleton via the *elt-6/elt-3* circuit). While the precise causal mechanisms linking H<sub>2</sub>S-related mitochondrial improvements with the *elt-6/elt-3* system and, subsequently, health span remains undefined, the mitochondrial mechanisms appear specific to the aging context; although we show aging mitochondrial decline and mtH<sub>2</sub>S acts through this TF circuit, inducing acute severe mitochondrial decline via toxic drugs fails to activate ELT-6 despite major structural fragmentation of mitochondria (SI Appendix, Fig. S14). Combined, our systems biological studies provide evidence that mtH<sub>2</sub>S improves mitochondrial health to alter *elt-6/elt-3* TFs, which likely act as a regulatory circuit governing cytoskeletal and peroxisomal gene clusters to, ultimately, modify health span.

## Discussion

H<sub>2</sub>S is a diatomic signaling molecule that promotes healthy aging in *C. elegans* (20), yet the underlying mechanisms and therapeutic viability across the lifecourse remains unclear. In this study, we have demonstrated that low mtH<sub>2</sub>S doses extend *C. elegans* health span, which associates with improved mitochondrial integrity from young adulthood into older age. Multiple elements of H<sub>2</sub>S metabolic pathways, and FoxO transcription factors emerged as mechanisms governing both life span and health span, whereas the Nrf2 antioxidant system is dispensable for mtH<sub>2</sub>S-induced health span extension. Adult mtH<sub>2</sub>S treatments also increase health span, predominantly in later life, and associates with rejuvenation of key features of the aging transcriptome, including mitochondrial function, cytoskeletal content, and peroxisomal metabolism, which appear to be controlled by a GATA transcription factor circuit.


The ability of large amounts of untargeted H<sub>2</sub>S, administered from birth, to enhance *C. elegans* life span and health span, is well documented (17–20). Our data reveal 1000-fold lower doses of a mitochondrion-targeted (TPP<sup>+</sup>-driven) H<sub>2</sub>S donor (28) can account for the life span, health span, and neuromuscular strength extension elicited by H<sub>2</sub>S. Thus, small amounts of H<sub>2</sub>S transported to the mitochondria are likely responsible for, and the site of action of, H<sub>2</sub>S effects on longevity. Temporal analysis further revealed mtH<sub>2</sub>S improved mitochondrion integrity beginning in earlier life that was maintained throughout the lifecourse, thus delaying one of the primary cellular hallmarks of aging (25). Conversely,

mtH<sub>2</sub>S did not increase movement rates or muscle strength until older age, likely owing to a lack of declines in muscle strength and habitual movement capacity during early adulthood, which is unsurprising, if decreasing H<sub>2</sub>S metabolism/synthesis is an aging pathology (56). These findings closely mirror the human phenotype, where a clear biphasic pattern of muscle aging emerges that involves early disruption to metabolic processes (57, 58) (as with *C. elegans* early loss of mitochondria integrity), which later manifests as exponential neuromuscular strength/physical capacity declines (again, as occurs in *C. elegans*) that exceeds rates of muscle mass losses (59, 60). As such, our data evidence that mtH<sub>2</sub>S can target the early mitochondrial metabolic perturbations during aging, possibly in preference over targeting respiratory function of existing mitochondria (61, 62) that attenuates the ensuing later changes in neuromuscular performance and health (25, 61, 62).

While the mechanisms regulating H<sub>2</sub>S-induced longevity have been explored (19), understanding the molecules governing health span is at least equally valuable, given the growing societal burden of life span – health span dissociation. Of the fourteen genes targeted for established roles in H<sub>2</sub>S biology, two clear functional themes emerged as mechanisms of mtH<sub>2</sub>S life span and health span extension. First, the FoxO/*daf-16* transcription factor is a highly conserved regulator of longevity across species (63) and in response to untargeted H<sub>2</sub>S (19). Our findings extend this to show *daf-16* is also required for mtH<sub>2</sub>S-related health span improvements. Second, although exogenous H<sub>2</sub>S could hypothetically bypass the biochemical need for endogenous H<sub>2</sub>S synthesis, the H<sub>2</sub>S metabolism genes examined (most strikingly the mitochondria localized 3-MST/*mpst-1*) were required for health span extension by mtH<sub>2</sub>S. Moreover, mtH<sub>2</sub>S-induced sulfide increases were prevented by *cth-2*, *mpst-1*, or *cbs-1* knockdown. Thus, while perhaps counterintuitive, presence of a functional H<sub>2</sub>S production system is a requirement for efficacious mtH<sub>2</sub>S treatments and might reflect the multifaceted cellular roles of the H<sub>2</sub>S enzymatic machinery and/or the diverse downstream consequences of loss of these enzymes (64). For example, H<sub>2</sub>S likely exerts at least part of its biological effects via cysteine persulfidation of multiple protein targets (65). The mitochondrially localized 3-MST/*mpst-1* is also a trans-persulfidase (66), thus H<sub>2</sub>S enzyme knockdown could prevent mtH<sub>2</sub>S-mediated persulfidation events, through which H<sub>2</sub>S might partially act. Interestingly, despite fatal consequences of complete ETHE1 knockout in higher mammals (45), RNAi knockdown of the mitochondrial H<sub>2</sub>S catabolic enzyme ETHE1/*ethe-1* strongly improved health span, possibly by mimicking mtH<sub>2</sub>S through mitochondrial accumulation of noncatabolized endogenous H<sub>2</sub>S. However, combined *ethe-1* RNAi and mtH<sub>2</sub>S ablates health span extension, and life span becomes shortened at higher, but not lower (1 to 10 nM) mtH<sub>2</sub>S doses, potentially due to toxic mtH<sub>2</sub>S accumulation, implying tight physiological range of mtH<sub>2</sub>S hormesis. Overall, these mechanistic insights add further evidence that place mitochondria at the center of H<sub>2</sub>S-regulated health span.

Activation of the Nrf2/*skn-1* antioxidant system has also been reported to control H<sub>2</sub>S-based longevity in *C. elegans* (48). Oxidative stress and reactive oxidant species might be a secondary consequence of tissue aging that may exacerbate, rather than cause aging health decline (67–70). While corroborating the requirement of the Nrf2 pathway for H<sub>2</sub>S life span extension, multiple components of the Nrf2/*skn-1* system, including the upstream activator DACF11/*wdr-23* and downstream effector GCLC/*gcs-1*, were not required for mtH<sub>2</sub>S health span improvements. Knocking down KRIT1/*kri-1*, which activates Nrf2 through redox species generation (44), did prevent mtH<sub>2</sub>S-induced health span extension. However, since several Nrf2 system components are not mechanisms of mtH<sub>2</sub>S health span extension, KRIT1/*kri-1* health span regulation likely relies





**Fig. 6.** Adult-onset mtH<sub>2</sub>S preserves health span through the ELT-6 GATA transcription factor circuit. (A) ELT-6 expression increases with aging and is significantly repressed with AP39 treatment compared to untreated animals in later-life. (B) Representative images of ELT-6 expression (*elt-6::mCherry*). (C) Preservation of age-related declines in mitochondrial integrity by AP39 correspond with attenuated ELT-6 expression (using *elt-6::mCherry* + *mito::GFP* coexpression reporter strain). (D) AP39-induced improvements in aging movement capacity is confirmed in *elt-6::mCherry* + *mito::GFP* animals, and correspond with lowered ELT-6 and improved mitochondrial integrity. RNAi against *elt-3* (E) and *elt-6* (F) prevents the health span-promoting effects of AP39. Panels A–D employed transgenic animals coexpressing *elt-6::mCherry* + *mito::GFP* in body-wall muscle, across 25 to 45 animals and two biological repeats. Panels (E and F) employed wild-type N2 animals. Movement rates are from 80–120 animals per condition, per time point. # denote significant effect of aging compared to untreated day 0 animals (#*P* < 0.05; ###*P* < 0.001). \* denote significant effect of treatment for within-day comparisons against untreated animals (\**P* < 0.05; \*\**P* < 0.01; \*\*\**P* < 0.001).

on its alternate functions in H<sub>2</sub>S synthesis (44). Importantly, these results highlight clear dissociation between the fundamental mechanisms governing life span vs. health span, indicating that oxidative stress protection pathways are dispensable for mtH<sub>2</sub>S-extended health span, but not life span.

The potential for developmentally programmed metabolic patterns with larval H<sub>2</sub>S treatments (21–23) renders the efficacy of postadulthood H<sub>2</sub>S therapies uncertain. We establish health span alone is extended with young adult mtH<sub>2</sub>S treatments, and when initiated in the presence of existing aging tissue pathologies. We, and others (26), found that mitochondrial fragmentation begins early in life (2 days postadulthood), and in this study we report that mtH<sub>2</sub>S improves health span when administered at this time. Similarly, muscle structural and proteostasis abnormalities occur later (4 days postadulthood), and mtH<sub>2</sub>S also displays efficacy during this therapeutic window. Mitochondrial H<sub>2</sub>S is, therefore, a viable adult-onset antiaging therapeutic opportunity. Transcriptomic studies aimed at understanding the mechanisms regulating adult mtH<sub>2</sub>S health span extension revealed clear distinctions from larval treatments. While administering mtH<sub>2</sub>S from L1 stage caused broad transcriptional features that diverged only slightly from wild-type animals only in older age, adult-onset mtH<sub>2</sub>S caused strong rejuvenation of the aging transcriptome toward “younger” gene profiles. Cluster analysis revealed adult mtH<sub>2</sub>S suppressed aging-induced increases in FoxO/*daf-16* pathway expression. While contrasting our observation that *daf-16* is a required effector of larval mtH<sub>2</sub>S treatment, suppression of aging *daf-16* levels with adult mtH<sub>2</sub>S implies divergent effects of FoxO induction during development vs. postdevelopment (71). This is consistent with

earlier reports that longevity caused by up-regulating FoxO/*daf-16* (via insulin receptor/*daf-2* mutation) is primarily established during larval development (72). Conversely, sarcopenia associates with postdevelopmental FoxO upregulation across species (58), corresponding with later life metabolic reprogramming to compensate for aging health decline (57, 58). Consistent with a potential beneficial aging effect of reduced postadulthood FoxO expression, are the moderate health span improvements we report with mtH<sub>2</sub>S-related *daf-16* suppression. This phenomenon underscores an unexplained paradox in aging research, whereby developmentally programmed life span extension (e.g., with increased FoxO signaling) presents at the expense of health span (7). Indeed, in people, FoxO genetic variants correlate with centenarians (73), yet impaired insulin signaling/ increased FoxO induced during adulthood causes serious clinical complications (e.g., diabetes, sarcopenia). Our data support a model whereby postdevelopmental, aging-induced increases in FoxO expression are harmful to health span (71), and drug interventions such as mtH<sub>2</sub>S that lower this response improve health while having minimal effect on longevity. Last, adult mtH<sub>2</sub>S also caused suppression of age-related increases in mitophagy and, most prominently, ribosomal biogenesis. Thus, mtH<sub>2</sub>S might mitigate unchecked mitophagy by preventing the mitochondrial dysfunction that promotes mitophagy with age (74), and promote improved translational efficiency as previously proposed to underpin physical activity-based anti-aging regimens (75, 76).

Adult mtH<sub>2</sub>S treatment also better maintained later-life expression of lowered aging transcriptomic profiles. Genes clustering to mitochondrion function featured heavily, lending further support to the central role of mitochondria in mtH<sub>2</sub>S-mediated health span.

Expression of muscle cytoskeletal components also decreased with age, which was minimized by adult mtH<sub>2</sub>S administration, with top ranked hub components largely represented by cytoskeletal (e.g., troponin regulation) factors. Given the later life temporal correlation between increased muscle structural genes and movement/strength capacity, mtH<sub>2</sub>S represents a promising neuromuscular health intervention in older age. Last, loss of metabolic plasticity is a common feature of aging across species (25). We found progressive reduction in expression of metabolic functional clusters across aging that was increased with adult onset mtH<sub>2</sub>S. Notably, metabolic cluster hub genes were strongly enriched for peroxisomal components. Peroxisomes are essential for proper functioning of all cell types, compartmentalizing enzymes regulating, e.g., fatty acid  $\beta$ -oxidation and hydrogen peroxide metabolism. Several facets of peroxisome dysfunction cause accelerated aging (77), and our data suggest peroxisome function can be sustained by mtH<sub>2</sub>S across life span. For example, *dhs-28* regulates age-dependent peroxisome loss, knockdown of which extends *C. elegans* life span (78), and our findings identify *dhs-28* as a top ranked, mtH<sub>2</sub>S-responsive hub component. Moreover, we confirm the mechanistic relevance of our identified peroxisomal transcriptomic targets by showing knockdown of the *ctl-2* hub gene prevents mtH<sub>2</sub>S-induced health span extension. Growing evidence also highlights inextricable cross talk between peroxisome and mitochondrial function (79). Indeed, caloric restriction-induced longevity [whose mechanisms converge with those of H<sub>2</sub>S (80)], requires mitochondria structural maintenance which, in turn, promotes peroxisome fatty acid oxidation (81). Our early-life improvements in mitochondrial integrity, combined with mitochondria localizing H<sub>2</sub>S, demonstrate improvements in mitochondrial integrity precede, and perhaps regulate, later life improvements in peroxisome capacity. Additionally, the lack of mechanistic regulation of health span by the Nrf2 antioxidant system implies that improved peroxisome fatty acid oxidation, as opposed to lowered reactive oxygen species generation, underpin peroxisomal effects of mtH<sub>2</sub>S on healthy aging.

Transcription factor-binding site analysis of our transcriptomic data identified the GATA TF circuit *elt-6/elt-3* as putatively regulating the health span benefits of adult onset mtH<sub>2</sub>S, which were subsequently verified by our mechanistic experiments. Previous work established age-related *elt-6* upregulation and downstream repression of *elt-3*, which accounted for altered expression of ~1,300 “aging” genes (54), which might comprise an evolutionarily conserved element of natural aging adaptation that promotes longevity, perhaps at the expense of health span, similarly to FoxO. Here, we confirm the relevance of this aging TF axis and establish *elt-6/elt-3* as mechanisms through which mtH<sub>2</sub>S and, either interrelatedly or independently *via bar-1/1*  $\beta$ -catenin, act to affect aging health. Interestingly, mitochondrial dysfunction per se is insufficient to explain *elt-6* upregulation, since severe toxin-induced mitochondrial insults fail to induce ELT-6. Thus, some as yet unknown specificity to age-related mitochondrial decline alters the *elt-6* pathway to induce gene expression changes that impair health span. Regardless, our combined functional, morphologic, transcriptomic, and mechanistic results point to a model where aging mitochondrial decline activates GATA TFs to alter gene expression, centered on cytoskeletal and peroxisomal gene clusters, to impair animal health. Crucially, mtH<sub>2</sub>S is an efficacious therapeutic approach for targeting the mitochondria to reverse this aging signaling axis and, ultimately, improve health span.

In conclusion, a systems biological approach identifies the mitochondria as the primary site of H<sub>2</sub>S action for slowing aging, with distinct molecular mechanisms underpinning life span vs. health span extension. Unlike life span, increased mtH<sub>2</sub>S health span does not require activation of the Nrf2 antioxidant system. Adult-onset mtH<sub>2</sub>S also increases health span alone, which

associates with unique aging transcriptomic signatures compared to life span-extending developmental mtH<sub>2</sub>S treatments, under the control of *elt-6/elt-3* GATA transcription factors. The emergence of neuromuscular health improvements in later life might also be underpinned by temporally correlated, mtH<sub>2</sub>S-responsive transcriptomic features of mitochondria, peroxisomal metabolism, and cytoskeletal function. Finally, the comparably lower mtH<sub>2</sub>S donor doses (vs. nontargeted NaGY4137; >3 orders of magnitude difference) required for aging health benefits, combined with efficacy in adult animals and high conservation of associated mechanisms, renders mtH<sub>2</sub>S a possible translational antiaging therapy.

## Materials and Methods

**C. elegans Maintenance and Experiment Design.** The strains used in this study were N2 wild-type and CB5600 (*ccls4251 (Pmyo-3::Ngfp-lacZ; Pmyo-3::Mtgfp)*) and were obtained from the Caenorhabditis Genetics Centre (CGC, University of Minnesota). For maintenance, *C. elegans* were cultured at 20 °C on OP50 *E. coli* seeded NGM agar plates, as previously described (82). For all experiments, the first day of adulthood was considered as Day 0.

For drug exposure experiments, unless stated otherwise, L1 worms synchronized by gravity floatation were cultured at 20 °C on OP50 *E. coli* seeded NGM plates containing either 100 nM AP39 + 0.01% DMSO, 100 nM or 100 mM NaGY4137, 0.01% DMSO or no drug. The mitochondrion-targeted H<sub>2</sub>S donor compound, AP39, was synthesized in-house by the Whiteman lab, as previously described (83, 84). The NaGY4137 (85) untargeted H<sub>2</sub>S donor compound was also synthesized in-house. Compound solutions were freshly prepared for every use and added to plates the evening before animal transfers. For developmental treatments, drug dosing was started from the L1 larval stage and continued throughout the life course. For adult drug treatments, gravity synchronized L1 larvae were grown on NGM agar seeded with OP50 only for 60 h to reach young adulthood, after which drug treatments were started at either day 0, day 2, or day 4 postadulthood. Adult animals were transferred every 48 h to fresh plates to remove progeny and maintain consistent food and drug concentrations.

**Survival Assay and Measures of C. elegans Locomotion and Maximal Strength Production.** Adult animals were scored and transferred to fresh plates every 48 h. The animals were scored as dead when they failed to move in response to stimulus with a needle. Animals that were lost, killed during transfer, or died as a result of (e.g.) egg laying defects were censored. Total animal numbers were n = 300 per condition, across three biological replicates. Locomotion assays were performed using WMicrotracker and maximal strength production was assessed using the ‘NemaFlex’ microfluidic device (36) (See [SI Appendix, Supplemental Methods](#)).

**Mitochondrial and Myofibrillar Imaging.** Mitochondria within body wall muscle cells of the CB5600 (*ccls4251 (Pmyo-3::Ngfp-lacZ; Pmyo-3::Mtgfp)*) strain were imaged using an Olympus CKX41 microscope (Olympus UK Ltd. London). The worms were imaged by GFP fluorescence microscopy at 40 $\times$  magnification. Approximately 20 to 30 animals per condition were placed in 20  $\mu$ L M9 on a microscope slide and immobilized with a cover slip. Images were taken of myofibers or mitochondria in body-wall muscle from both head and tail regions of every animal and visually classified as either well-networked, moderately fragmented, or severely fragmented (for mitochondrial quantification), or organized, moderately disorganized, and severely disorganized (for myofibrillar quantification) as previously described (26, 86). The overall proportion of mitochondrial or myofibrillar classifications was obtained by normalizing to the total muscle cell count within each treatment condition (~150 to 300 muscle cells per condition from 30 to 60 animals per time point) across two biological replicates.

**Measurement of Citrate Synthase Activity.** Wild-type N2 animals were roughly age synchronized as previously described and grown for ~60 h to young adulthood on fresh OP50 bacterial lawns 20 °C. Animals were transferred to fresh OP50 plates every 48 h to remove progeny and prevent population starvation, and 50 animals collected per condition, per time point (days 0, 2, 4, and 12 postadulthood) and per replicate. Citrate synthase activity (CS) was measured in isolated mitochondrial pellets, as described in Supplemental methods section.

**RNA Interference Protocols.** All RNAi experiments were performed using age synchronized L1 larval stage animals by gravity flotation and grown for 60 h on NGM agar plates containing 1 mM IPTG, 50 µg/mL ampicillin. The plates were seeded with 200 µL HT115 (DE3) bacteria expressing double-stranded RNA against the genes screened. The Ahringer RNAi library (87) was utilized, purchased from Source Bioscience (Cambridge, UK). HT115 (DE3) bacteria containing the empty L4440 plasmid vector was used as controls. Full details of each RNAi protocol for health span/life span screens, or plate-based experiments can be viewed in *SI Appendix, Supplemental Methods* section.

**RNA Isolation for Next-Generation Sequencing.** Synchronized worms were grown on NGM agar plates until young adulthood and treated with AP39 mtH<sub>2</sub>S from either L1 or day 0, as described above. On sample collection day, 100 worms were manually picked and added to 1 mL TRIzol™ Reagent (ThermoFisher Scientific, Loughborough, UK) prior to RNA extractions (see *SI Appendix, Supplemental Methods* section for details).

**RNA-seq Data Analyses.** After RNA sequencing data preprocessing (see *SI Appendix, Supplemental Methods* section), the DESeq2 package for R (88) was used to test for differential gene expression. Establishing approaches to adaptive shrinkage methods (89) and control for false discovery rate (FDR) were employed. DESeq2 was applied to normalized counts to group by expression profile any gene differentially regulated between treatments and/or time points. Functional enrichment analysis of defined gene clusters was then undertaken using the gprofiler2 package for R (90). Each gene cluster was also input into the Online Search Tool for Retrieval of Interacting Genes/Proteins (STRING, v11.5; ref. 91) to infer respective PPI networks. Full details of the bioinformatic pipeline employed are provided in Supplemental methods section.

**7-azido-4-Methylcoumarin Measures of Total Sulfide Levels.** In all, 120 animals were picked into M9 buffer in 1.5 mL low-bind eppendorphs and washed three times with 1 mL sterile M9 to clear bacterial debris and progeny. Samples were snap-frozen in 40 µL M9 and stored at -80 °C until analysis (within 1 wk). Sulfide content was assessed as described previously (13, 86) as described in *SI Appendix, Supplemental Methods* section.

**ELT-6 Fluorescent Reporter Quantification.** The SD1550 strain harboring an *elt-6* fluorescent promoter and mitochondrial GFP (*ccls4251 [(pSAK2) myo-3p::GFP::LacZ::NLS + (pSAK4) myo-3p::mitochondrial GFP + dpy-20(+)] I.stls10178 [elt-6p::HIS-24::mCherry + unc-119(+)]*) was imaged on an upright epifluorescent microscope (BX43, Olympus Life Science, UK). All *elt-6* images were taken with *mCherry* fluorescence at 500-ms exposure and GFP fluorescence set to 50-ms exposure for mitochondrial images. Single images were taken from the head for ELT-6, as the sole site of ELT-6 reporter expression pattern, and from head and tail regions for mitochondrial characterisation across 40-60 animals per condition, per time point. Mitochondrial images were analyzed as detailed above, and ELT-6 images were quantified in ImageJ by performing integrated density quantification on each fluorescent image, subtracting background fluorescence.

**Mitochondrial Toxic Stress Assays in ELT-6 Transgenic Reporter Animals.** Age-synchronized SD1550 animals were grown to young adulthood on 33-mm NGM plates seeded with OP50 bacteria. Approximately 30 day 0 adults were then picked into 40 µL of either 100 µM hydrogen peroxide (Sigma, UK; 7722-84-1) or 5 mM sodium arsenite (Santa Cruz, DE; 7784-46-5) diluted in M9 for 1- and 2-h exposures, respectively. For rotenone and antimycin A exposures, animals were picked into 40 µL 50 µM or 100 µM concentrations, respectively, diluted in 20 mg/mL OP50/NGM bacteria and incubated for 4 h. Tubes were then washed three times with M9 before animals were pipetted onto slides and immobilized by a coverslip. Both ELT-6 and mitochondrial images were then captured and analyzed as detailed above.

1. E. Nash, Health Expectancies at Birth and at Age 65 in the United Kingdom: 2009-2011. *Office for National Statistics* 1, 1-16 (2014).
2. A. Garmany, S. Yamada, A. Terzic, Longevity leap: Mind the healthspan gap. *NPJ Regen. Med.* 6, 57 (2021).
3. S. Chang *et al.*, Health span or life span: The role of patient-reported outcomes in informing health policy. *Health Policy* 100, 96-104 (2011).
4. M. Lucanic, G. J. Lithgow, S. Alavez, Pharmacological lifespan extension of invertebrates. *Ageing Res. Rev.* 12, 445-458 (2013).
5. P. Kapahi, M. Kaerberlein, M. Hansen, Dietary restriction and lifespan: Lessons from invertebrate models. *Ageing Res. Rev.* 39, 3-14 (2017).

**Mitochondrial Superoxide Assessment.** Superoxide levels were measured using MitoSOX (Invitrogen, UK) as described previously (86, 92). For day 0 measures, animals were grown on OP50 plates until L3 larval stage, where ~30 animals were then picked onto petri plates + OP50 seeded with a final plate concentration of 10 µM MitoSOX and left to incubate in the dark for 24 h. The same exposures were performed for day 4 and day 10 measures (i.e., day 3 and day 9 adults picked onto MitoSOX plates for 24 h, respectively). On the day of imaging, animals were washed from plates with M9 buffer into 1.5 mL low-bind tubes and washed three times to clear the outer cuticle of probe. Animals were then placed on OP50 plates for 1-h to clear residual probe from the gut. Animals were then picked into 20 µL M9 buffer on glass slides with glass coverslip. Images were taken with a 40× objective with green light excitation and a 1-s exposure rate. The terminal bulb was manually selected in ImageJ and integrated fluorescence density was normalized to the total area of analysis and background fluorescence removed.

**Statistics and Data Analysis.** Statistics and graph generation were performed in GraphPad Prism 9. Significance was determined by paired *t* test or 2-way ANOVA, with post hoc multiple comparison tests. For survival analyses, the Log-Rank (Mantel Cox) test was used.

**Data, Materials, and Software Availability.** All study data are included in the article and/or supporting information. The raw RNA sequencing data can be found within the NCBI BioProject database (<https://www.ncbi.nlm.nih.gov/bioproject/>) under the Sequence Read Archive (SRA) accession PRJNA996496 (93).

**ACKNOWLEDGMENTS.** We would like to acknowledge Caroline Coffey for the technical assistance provided toward the mechanistic experiments of this work. A.R.V., M.W., and T.E. were supported by the US Army Research Office (W911NF-19-1-0235). L.S., M.W., and T.E. were supported by the United Mitochondrial Disease Foundation (PI-19-0985). L.S. was also supported by the University of Exeter Jubilee Scholarship. M.C., N.J.S., and T.E. were supported by the UK Space Agency (ST/R005737/1). N.J.S. and T.E. were supported by BBSRC (BB/N015894/1). S.A.V. was supported by NASA (NNX15AL16G). N.J.S. was supported by grants from NASA [NSSC22K0250; NSSC22K0278] and acknowledges the support of the Osteopathic Heritage Foundation through funding for the Osteopathic Heritage Foundation Ralph S. Licklider, D.O., Research Endowment in the Heritage College of Osteopathic Medicine.

Author affiliations: <sup>a</sup>Public Health and Sport Sciences, Faculty of Health and Life Sciences, University of Exeter, Exeter EX1 2LU, United Kingdom; <sup>b</sup>University of Exeter Medical School, Faculty of Health and Life Sciences, University of Exeter, Exeter EX1 2LU, United Kingdom; <sup>c</sup>Medical Research Council Versus Arthritis Centre for Musculoskeletal Ageing Research, Nottingham Biomedical Research Center, School of Medicine, Royal Derby Hospital, University of Nottingham, Derby DE22 3DT, United Kingdom; <sup>d</sup>School of Chemistry and Biosciences, Faculty of Life Sciences, University of Bradford, Bradford BD7 1DP, United Kingdom; <sup>e</sup>Department of Chemical Engineering, Texas Tech University, Lubbock, TX 79409; <sup>f</sup>Department of Electrical Engineering, Texas Tech University, Lubbock, TX 79409; <sup>g</sup>Lancaster University Medical School, Lancaster University, Lancaster LA1 4YW, United Kingdom; <sup>h</sup>Chair of Pharmacology, Section of Medicine, University of Fribourg, Fribourg CH-1700, Switzerland; and <sup>i</sup>Ohio Musculoskeletal and Neurologic Institute, Heritage College of Osteopathic Medicine, Ohio University, Athens, OH 45701

Author contributions: N.J.S., M.W., and T.E. designed research; A.R.V., L.S., M.C., M.R., T.A., C.J.G., and N.G. performed research; R.T., S.A.V., C.S., and M.W. contributed new reagents/analytic tools; A.R.V., M.C., C.R.G.W., M.R., N.J.S., M.W., and T.E. analyzed data; and A.R.V., N.J.S., and T.E. wrote the paper.

Competing interest statement: M.W. and R.T. have intellectual property (patents) on sulfide delivery molecules and their use. M.W. is a co-founder and CSO of MitORX Therapeutics, Oxford. S.A.V. and M.R. are co-founders of NemaLife Inc., and the microfluidic devices used in this study have been licensed for commercialization. S.A.V., M.R., and T.A. are named inventors on the microfluidic devices.

6. M. Hansen, B. K. Kennedy, Does longer lifespan mean longer healthspan? *Trends Cell Biol.* 26, 565-568 (2016).
7. A. Bansal, L. J. Zhu, K. Yen, H. A. Tissenbaum, Uncoupling lifespan and healthspan in *Caenorhabditis elegans* longevity mutants. *Proc. Natl. Acad. Sci. U.S.A.* 112, E277-E286 (2015).
8. R. Wang, Physiological implications of hydrogen sulfide: A Whiff exploration that blossomed. *Physiol. Rev.* 92, 791-896 (2012).
9. M. R. Filipovic, J. Zivanovic, B. Alvarez, R. Banerjee, Chemical biology of H<sub>2</sub>S signaling through persulfidation. *Chem. Rev.* 118, 1253-1337 (2018).
10. B. D. Paul, S. H. Snyder, H<sub>2</sub>S signalling through protein sulfhydration and beyond. *Nat. Rev. Mol. Cell Biol.* 13, 499-507 (2012).

11. C. Szabó, Hydrogen sulphide and its therapeutic potential. *Nat. Rev. Drug. Discov.* **6**, 917–935 (2007).
12. J. L. Wallace, R. Wang, Hydrogen sulfide-based therapeutics: Exploiting a unique but ubiquitous gas transmitter. *Nat. Rev. Drug. Discov.* **14**, 329–345 (2015).
13. R. A. Ellwood *et al.*, Mitochondrial hydrogen sulfide supplementation improves health in the C. elegans Duchenne muscular dystrophy model. *Proc. Natl. Acad. Sci. U.S.A.* **118**, e2018342118 (2021).
14. B. C. Fox *et al.*, The mitochondria-targeted hydrogen sulfide donor AP39 improves health and mitochondrial function in a C. elegans primary mitochondrial disease model. *J. Inherit. Metab. Dis.* **44**, 367–375 (2021).
15. J. L. Wallace, J. G. P. Ferraz, M. N. Muscara, Hydrogen sulfide: An endogenous mediator of resolution of inflammation and injury. *Antioxid. Redox Sign.* **17**, 58–67 (2012).
16. S. Mani *et al.*, Decreased endogenous production of hydrogen sulfide accelerates atherosclerosis. *Circulation* **127**, 2523–2534 (2013).
17. D. L. Miller, M. B. Roth, Hydrogen sulfide increases thermotolerance and lifespan in Caenorhabditis elegans. *Proc. Natl. Acad. Sci. U.S.A.* **104**, 20618–20622 (2007).
18. B. Qabazard *et al.*, C. elegans aging is modulated by hydrogen sulfide and the sulfhydrylase/cysteine Synthase *cysl-2*. *PLoS One* **8**, e80135 (2013).
19. B. Qabazard *et al.*, Hydrogen sulfide is an endogenous regulator of aging in Caenorhabditis elegans. *Antioxid. Redox Sign.* **20**, 2621–2630 (2014).
20. L. T. Ng *et al.*, Lifespan and healthspan benefits of exogenous H<sub>2</sub>S in C. elegans are independent from effects downstream of eat-2 mutation. *NPJ Aging Mech. Dis.* **6**, 6 (2020).
21. S. Pradhan, S. Quilez, K. Homer, M. Hendricks, Environmental programming of adult foraging behavior in C. elegans. *Curr. Biol.* **29**, 2867–2879.e4 (2019).
22. A. Dillin *et al.*, Rates of behavior and aging specified by mitochondrial function during development. *Science* **298**, 2398–2401 (2002).
23. A. Dillin, D. K. Crawford, C. Kenyon, Timing requirements for Insulin/IGF-1 signaling in C. elegans. *Science* **298**, 830–834 (2002).
24. C. Szabo, A. Papapetropoulos, International union of basic and clinical pharmacology. CII: Pharmacological modulation of H<sub>2</sub>S levels: H<sub>2</sub>S donors and H<sub>2</sub>S biosynthesis inhibitors. *Pharmacol. Rev.* **69**, 497–564 (2017).
25. C. López-Otín, M. A. Blasco, L. Partridge, M. Serrano, G. Kroemer, The hallmarks of aging. *Cell* **153**, 1194–1217 (2013).
26. C. J. Gaffney *et al.*, Greater loss of mitochondrial function with ageing is associated with earlier onset of sarcopenia in C. elegans. *Aging Albany NY* **10**, 3382–3396 (2018).
27. B. A. I. Payne, P. F. Chinnery, Mitochondrial dysfunction in aging: Much progress but many unresolved questions. *Biochim. Biophys. Acta* **1847**, 1347–1353 (2015).
28. B. Szczesny *et al.*, AP39, a novel mitochondria-targeted hydrogen sulfide donor, stimulates cellular bioenergetics, exerts cytoprotective effects and protects against the loss of mitochondrial DNA integrity in oxidatively stressed endothelial cells in vitro. *Nitric Oxide* **41**, 120–130 (2014).
29. E. J. Metter, L. A. Talbot, M. Schrager, R. Conwit, Skeletal muscle strength as a predictor of all-cause mortality in healthy men. *J. Gerontol. Ser. B* **57**, B359–B365 (2002).
30. J.-H. Hamm *et al.*, C. elegans maximum velocity correlates with healthspan and is maintained in worms with an insulin receptor mutation. *Nat. Commun.* **6**, 8919 (2015).
31. F. L. Calvert, T. P. Crowe, B. F. S. Grenyer, Dialogical reflexivity in supervision: An experiential learning process for enhancing reflective and relational competencies. *Clin. Superv.* **35**, 1–21 (2016).
32. K. T. Tan, S.-C. Luo, W.-Z. Ho, Y.-H. Lee, Insulin/IGF-1 receptor signaling enhances biosynthetic activity and fat mobilization in the initial phase of starvation in adult male C. elegans. *Cell Metab.* **14**, 390–402 (2011).
33. J. A. Rollins, A. C. Howard, S. K. Dobbins, E. H. Washburn, A. N. Rogers, Assessing health span in Caenorhabditis elegans: Lessons from short-lived mutants. *J. Gerontol. Ser. B* **72**, 473–480 (2017).
34. D. B. Sinha, Z. S. Pincus, High temporal resolution measurements of movement reveal novel early-life physiological decline in C. elegans. *PLoS One* **17**, e0257591 (2022).
35. E. G. Artero *et al.*, A prospective study of muscular strength and all-cause mortality in men with hypertension. *J. Am. Coll. Cardiol.* **57**, 1831–1837 (2011).
36. T. Etheridge *et al.*, The integrin-adhesome is required to maintain muscle structure, mitochondrial ATP production, and movement forces in Caenorhabditis elegans. *FASEB J.* **29**, 1235–1246 (2015).
37. M. Rahman *et al.*, NemaFlex: A microfluidics-based technology for standardized measurement of muscular strength of C. elegans. *Lab. Chip.* **18**, 2187–2201 (2018).
38. L. Lesanpezeshki *et al.*, Investigating the correlation of muscle function tests and sarcomere organization in C. elegans. *Skelet. Muscle* **11**, 20 (2021).
39. I. Mohammed, M. D. Hollenberg, H. Ding, C. R. Triggle, A critical review of the evidence that metformin is a putative anti-aging drug that enhances healthspan and extends lifespan. *Front. Endocrinol.* **12**, 718942 (2021).
40. S. Alavez, M. C. Vantipalli, D. J. S. Zucker, I. M. Klang, G. J. Lithgow, Amyloid-binding compounds maintain protein homeostasis during ageing and extend lifespan. *Nature* **472**, 226–229 (2011).
41. E. J. E. Kim, S.-J. V. Lee, Recent progresses on anti-aging compounds and their targets in Caenorhabditis elegans. *Transl. Med. Aging* **3**, 121–124 (2019).
42. D. F. Bennett *et al.*, Rilmenidine extends lifespan and healthspan in Caenorhabditis elegans via a nischarin 11-imidazole receptor. *Aging Cell* **22**, e13774 (2023).
43. S. Larsen *et al.*, Biomarkers of mitochondrial content in skeletal muscle of healthy young human subjects. *J. Physiol.* **590**, 3349–3360 (2012).
44. Y. Wei, C. Kenyon, Roles for ROS and hydrogen sulfide in the longevity response to germline loss in Caenorhabditis elegans. *Proc. Natl. Acad. Sci. U.S.A.* **113**, E2832–E2841 (2016).
45. V. Tiranti *et al.*, Loss of ETHE1, a mitochondrial dihydrogenase, causes fatal sulfide toxicity in ethylmalonic encephalopathy. *Nat. Med.* **15**, 200–205 (2009).
46. A. Kimura *et al.*, Aryl hydrocarbon receptor in combination with Stat1 regulates LPS-induced inflammatory responses. *J. Exp. Med.* **206**, 2027–2035 (2009).
47. S. S. Lee, S. Kennedy, A. C. Tolonen, G. Ruvkun, DAF-16 target genes that control C. elegans life-span and metabolism. *Science* **300**, 644–647 (2003).
48. D. L. Miller, M. W. Budde, M. B. Roth, HIF-1 and SKN-1 coordinate the transcriptional response to hydrogen sulfide in Caenorhabditis elegans. *PLoS One* **6**, e25476 (2011).
49. J. Y. Lo, B. N. Spatola, S. P. Curran, WDR23 regulates NRF2 independently of KEAP1. *PLoS Genet.* **13**, e1006762 (2017).
50. L. Tang, K. P. Choe, Characterization of *skn-1/wdr-23* phenotypes in Caenorhabditis elegans; pleiotropy, aging, glutathione, and interactions with other longevity pathways. *Mech. Ageing Dev.* **149**, 88–98 (2015).
51. C. S. Deane *et al.*, Transcriptomic meta-analysis of disuse muscle atrophy vs. resistance exercise-induced hypertrophy in young and older humans. *J. Cachexia Sarcopenia Muscle* **12**, 629–645 (2021).
52. C. R. G. Willis *et al.*, Network analysis of human muscle adaptation to aging and contraction. *Aging Albany NY* **12**, 740–755 (2020).
53. C. R. G. Willis *et al.*, Transcriptomic adaptation during skeletal muscle habituation to eccentric or concentric exercise training. *Sci. Rep.* **11**, 23930 (2021).
54. Y. V. Budovskaya *et al.*, An elt-3/elt-5/elt-6 GATA transcription circuit guides aging in C. elegans. *Cell* **134**, 291–303 (2008).
55. M. L. van der Bent *et al.*, Loss-of-function of  $\beta$ -catenin bar-1 slows development and activates the Wnt pathway in Caenorhabditis elegans. *Sci. Rep.* **4**, 4926 (2014).
56. S. E. Wilkie, G. Borland, R. N. Carter, N. M. Morton, C. Selman, Hydrogen sulfide in ageing, longevity and disease. *Biochem. J.* **478**, 3485–3504 (2021).
57. E. Migliavacca *et al.*, Mitochondrial oxidative capacity and NAD<sup>+</sup> biosynthesis are reduced in human sarcopenia across ethnicities. *Nat. Commun.* **10**, 5808 (2019).
58. A. Börsch *et al.*, Molecular and phenotypic analysis of rodent models reveals conserved and species-specific modulators of human sarcopenia. *Commun. Biol.* **4**, 194 (2021).
59. J. Lexell, C. C. Taylor, M. Sjöström, What is the cause of the ageing atrophy? Total number, size and proportion of different fiber types studied in whole vastus lateralis muscle from 15- to 83-year-old men. *J. Neurosci.* **84**, 275–294 (1988).
60. E. Volpi, R. Nazemi, S. Fujita, Muscle tissue changes with aging. *Curr. Opin. Clin. Nutr.* **7**, 405–410 (2004).
61. C. Porter *et al.*, Mitochondrial respiratory capacity and coupling control decline with age in human skeletal muscle. *Am. J. Physiol. Endocrinol. Metab.* **309**, E224–E232 (2015).
62. K. J. Jacob *et al.*, Mitochondrial content, but not function, is altered with a multimodal resistance training protocol and adequate protein intake in leucine-supplemented pre/frail women. *Front. Nutr.* **7**, 619216 (2021).
63. D. van Heemst, Insulin, IGF-1 and longevity. *Aging Dis.* **1**, 147–157 (2010).
64. N. Nagahara, Multiple role of 3-mercaptopyruvate sulfurtransferase: Antioxidative function, H<sub>2</sub>S and polysulfide production and possible SO<sub>x</sub> production. *Brit. J. Pharmacol.* **175**, 577–589 (2018).
65. J. Zivanovic *et al.*, Selective persulfide detection reveals evolutionarily conserved antiaging effects of S-sulfhydration. *Cell Metab.* **30**, 1152–1170.e13 (2019).
66. K. Hanaoka *et al.*, Discovery and mechanistic characterization of selective inhibitors of H<sub>2</sub>S-producing Enzyme: 3-mercaptopyruvate sulfurtransferase (3MST) targeting active-site cysteine persulfide. *Sci Rep-uk* **7**, 40227 (2017).
67. R. Buffenstein, Y. H. Edrey, T. Yang, J. Mele, The oxidative stress theory of aging: Embattled or invincible? Insights from non-traditional model organisms. *Age* **30**, 99–109 (2008).
68. V. N. Gladyshev, The free radical theory of aging is dead. Long live the damage theory! *Antioxid. Redox Sign.* **20**, 727–731 (2014).
69. H. J. Shields, A. Traa, J. M. V. Raamsdonk, Beneficial and detrimental effects of reactive oxygen species on lifespan: A comprehensive review of comparative and experimental studies. *Front. Cell Dev. Biol.* **9**, 628157 (2021).
70. J. M. V. Raamsdonk, S. Hekimi, Reactive oxygen species and aging in Caenorhabditis elegans: Causal or casual relationship? *Antioxid. Redox Sign.* **13**, 1911–1953 (2010).
71. S. Li *et al.*, DAF-16 stabilizes the aging transcriptome and is activated in mid-aged Caenorhabditis elegans to cope with internal stress. *Aging Cell* **18**, e12896 (2019).
72. C. T. Murphy, P. J. Hu, Insulin/Insulin-like growth factor signaling in C. elegans. *Wormbook*, 1–43 (2013).
73. R. Martins, G. J. Lithgow, W. Link, Long live FOXO: Unraveling the role of FOXO proteins in aging and longevity. *Aging Cell* **15**, 196–207 (2016).
74. G. Chen, G. Kroemer, O. Kepp, Mitophagy: An emerging role in aging and age-associated diseases. *Front. Cell Dev. Biol.* **8**, 200 (2020).
75. B. E. Phillips *et al.*, Molecular networks of human muscle adaptation to exercise and age. *PLoS Genet.* **9**, e1003389 (2013).
76. M. S. Brook *et al.*, Synchronous deficits in cumulative muscle protein synthesis and ribosomal biogenesis underlie age-related anabolic resistance to exercise in humans. *J. Physiol.* **594**, 7399–7417 (2016).
77. N. M. Deori, A. Kale, P. K. Maurya, S. Nagotu, Peroxisomes: Role in cellular ageing and age related disorders. *Biogerontology* **19**, 303–324 (2018).
78. D. A. Dolese *et al.*, Degradative tubular lysosomes link pexophagy to starvation and early aging in C. elegans. *Autophagy* **18**, 1522–1533 (2021).
79. M. Fransen, C. Lismont, P. Walton, The peroxisome-mitochondria connection: How and why? *Int. J. Mol. Sci.* **18**, 1126 (2017).
80. C. Hine *et al.*, Endogenous hydrogen sulfide production is essential for dietary restriction benefits. *Cell* **160**, 132–144 (2015).
81. H. J. Weir *et al.*, Dietary restriction and AMPK increase lifespan via mitochondrial network and peroxisome remodeling. *Cell Metab.* **26**, 884–896.e5 (2017).
82. S. Brenner, The genetics of Caenorhabditis elegans. *Genetics* **77**, 71–94 (1974).
83. S. L. Trionnaire *et al.*, The synthesis and functional evaluation of a mitochondria-targeted hydrogen sulfide donor, (10-oxo-10-(4-(3-thioxo-3 H-1,2-dithiol-5-yl)phenoxy)decyl)triphenylphosphonium bromide (AP39). *Medchemcomm* **5**, 728–736 (2014).
84. B. E. Alexander *et al.*, Investigating the generation of hydrogen sulfide from the phosphonamidodithioate slow-release donor GYY4137. *Medchemcomm* **6**, 1649–1655 (2015).
85. L. Li *et al.*, Characterization of a novel, water-soluble hydrogen sulfide-releasing molecule (GYY4137). *Circulation* **117**, 2351–2360 (2008).
86. R. A. Ellwood *et al.*, Sulfur amino acid supplementation displays therapeutic potential in a C. elegans model of Duchenne muscular dystrophy. *Commun. Biol.* **5**, 1255 (2022).
87. A. G. Fraser *et al.*, Functional genomic analysis of C. elegans chromosome I by systematic RNA interference. *Nature* **408**, 325–330 (2000).
88. M. I. Love, W. Huber, S. Anders, Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. *Genome Biol.* **15**, 550 (2014).
89. M. Stephens, False discovery rates: A new deal. *Biostatistics* **18**, kxw041 (2016).
90. L. Kolberg, U. Raudvere, I. Kuzmin, J. Vilo, H. Peterson, profiler2—An R package for gene list functional enrichment analysis and namespace conversion toolset g:Profiler. *F1000Res* **9**, ELIXIR-709 (2020).
91. D. Szklarczyk *et al.*, STRING v11: Protein–protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. *Nucleic Acids Res.* **47**, gky1131 (2018).
92. S. Dingley *et al.*, Mitochondrial respiratory chain dysfunction variably increases oxidant stress in Caenorhabditis elegans. *Mitochondrion* **10**, 125–136 (2010).
93. A. R. Vintila *et al.*, Effect of mitochondrial sulfide on C. elegans transcriptome across the lifecycle. *NCBI BioProject*. <https://www.ncbi.nlm.nih.gov/bioproject/?term=PRJNA996496>. Deposited 19 July 2023.